Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Let's start fresh here guys ...

<< Previous

Bullboard Posts

Next >>

Comment by MasterAlgaeon Aug 20, 2021 9:24am

136 Views

Post# 33738881

RE:Let's start fresh here guys ...

The science needs to be supported by a new WOMAC study first to see if the pain reduction is still significent at lower doses. Pain reduction might not be significent at 75 mg.

What is the lowest amount of H2S that provides significent pain reduction in one pill a day? If 75 does not privide significent pain reduction for 24 hours then no point in going forward with the other tests is there?

MrMugsy wrote: You can see from the reduced garbage on this site ... that the trash man came and cleaned the streets. Let's get back to discussions. Sure we'll disagree but let's get back to what this place was before all the panic.

1. review data by Oct 4 and decide on path forward.
2. if data shows a potential to reduce dose then apply for AME (30 days - by mid-November)
3. AME at 75, 50, 25, 10, 5 mg (done by March) while also working on fast-track for 352 replacement ... multiple paths for this drug.
4. Phase 2 (60-80 people)
5. Phase 3 ... hopefully starting before 2022 is over ... that would be nice ! Hopefully P3 is reduced from a P2/3 as dose ranging shouldn't be required (just an assumption on my part).

-----

During this time, progress on Respiratory/COVID, FAP and Ulcerative Colitis.
I'm guessing our new IBD drug with its "remarkable anti-inflammatory properties" will be used here.

Would be nice to announce a an initial path for Alzheimer's/Parkinson's as well. If Biogen was any indication of what the market was looking for ... they pumped up Biogen's value on the FDA greenlight by $20B. Sure it came down since but that's only because investors realized the Biogen's path wasn't all that great. I'm sure we can do so much better.

EOM